Comparative Outcomes of Donor Graft CD34<sup>+</sup> Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation
Marcelo C. Pasquini(Cleveland Clinic), Robert J. Soiffer(Dana-Farber Cancer Institute), Hillard M. Lazarus(University Hospitals of Cleveland), Shelly Carter(European Society for Blood and Marrow Transplantation), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Adam Mendizabal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Carolyn A. Keever-Taylor(Medical College of Wisconsin), Lindsey R. Baden(Brigham and Women's Hospital), Mary M. Horowitz(Medical College of Wisconsin), John R. Wingard(University of Florida Health), Richard J. O’Reilly(Memorial Sloan Kettering Cancer Center), Steven M. Devine(National Marrow Donor Program)
Cited by 157
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k